Deutsch English Français

Contact

EP4240354

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP4240354

EP4240354 - RAF INHIBITOR FOR TREATING LOW GRADE GLIOMA [Right-click to bookmark this link]
Status	Examination is in progress Status updated on 16.01.2026 Database last updated on 09.04.2026
Former	Request for examination was made Status updated on 11.08.2023
Former	The international publication has been made Status updated on 13.05.2022
Most recent event Tooltip	27.02.2026	Change - applicant	published on 01.04.2026 [2026/14]
Applicant(s)	For all designated states Day One Biopharmaceuticals, Inc. 1800 Sierra Point Parkway, Suite 200 Brisbane, CA 94005 / US
	For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US
	For all designated states THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 75 Francis Street Boston, MA 02115 / US
	[2026/14]
Former [2023/37]	For all designated states Day One Biopharmaceuticals, Inc. 2000 Sierra Point Parkway, Suite 501 Brisbane, CA 94005 / US
	For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US
	For all designated states THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 75 Francis Street Boston, MA 02115 / US
Inventor(s)	01 / BLACKMAN, Samuel C. Eastsound, Washington 98245 / US
	02 / WRIGHT, Karen D. Boston, Massachusetts 02215 / US
	03 / HAAS-KOGAN, Daphne Adele Boston, Massachusetts 02215 / US
	[2023/37]
Representative(s)	Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
	[2023/37]
Application number, filing date	21890193.2	05.11.2021
	[2023/37]
	WO2021US58337
Priority number, date	US202063110724P	06.11.2020 Original published format: US 202063110724 P
	US202163138285P	15.01.2021 Original published format: US 202163138285 P
	[2023/37]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2022099074
	Date:	12.05.2022
	Language:	EN
	[2022/19]
	Type:	A1 Application with search report
	No.:	EP4240354
	Date:	13.09.2023
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 12.05.2022 takes the place of the publication of the European patent application.
	[2023/37]
Search report(s)	International search report - published on:	US	12.05.2022
	(Supplementary) European search report - dispatched on:	EP	14.06.2024
Classification	IPC:	A61K31/4375, A61K31/44, A61K31/505, A61K45/06, A61P35/00, A61K31/506	[2024/29]
	CPC:	A61K31/506 (EP,KR,US); A61K45/06 (EP,US); A61P35/00 (EP,KR,US)
	Former IPC [2023/37]	A61K31/4375, A61K31/44, A61K31/505
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/37]
Title	German:	RAF-HEMMER ZUR BEHANDLUNG VON GLIOMEN NIEDRIGER QUALITÄT	[2023/37]
	English:	RAF INHIBITOR FOR TREATING LOW GRADE GLIOMA	[2023/37]
	French:	INHIBITEUR DE RAF POUR TRAITER LE GLIOME DE BAS GRADE	[2023/37]
Entry into regional phase	10.05.2023	National basic fee paid
	10.05.2023	Search fee paid
	10.05.2023	Designation fee(s) paid
	10.05.2023	Examination fee paid
Examination procedure	10.05.2023	Examination requested [2023/37]
	30.12.2024	Amendment by applicant (claims and/or description)
	30.12.2024	Date on which the examining division has become responsible
	19.01.2026	Despatch of a communication from the examining division (Time limit: M04)
Fees paid	Renewal fee
	27.11.2023	Renewal fee patent year 03
	27.11.2024	Renewal fee patent year 04
	26.11.2025	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A] WO2013144923 (TAKEDA PHARMACEUTICAL et al.) [A] 1-15 * claim - *
		[A] YU SUN: "A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas", NEURO-ONCOLOGY, 12 January 2017 (2017-01-12), US, pages now261, XP093169868, ISSN: 1522-8517, DOI: 10.1093/neuonc/now261 [A] 1-15 * page 784 * DOI: http://dx.doi.org/10.1093/neuonc/now261
		[I] DE BLANK PETER ET AL: "Management of pediatric low-grade glioma", vol. 31, no. 1, 1 February 2019 (2019-02-01), US, pages 21 - 27, XP093114016, ISSN: 1040-8703, Retrieved from the Internet DOI: 10.1097/MOP.0000000000000717 [I] 1-15 * page 6 * DOI: http://dx.doi.org/10.1097/MOP.0000000000000717
		[A] WENDY L. SEE: "Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy", 1 January 2018 (2018-01-01), pages 323 - 332, XP093169789, ISBN: 978-0-12-812100-9, Retrieved from the Internet DOI: 10.1016/B978-0-12-812100-9.00022-X [A] 1-15 * page 327 *
		[A] KOWALEWSKI ADAM ET AL: "Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm", TARGETED ONCOLOGY, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 15, no. 4, 9 July 2020 (2020-07-09), pages 531 - 540, XP037222176, ISSN: 1776-2596, [retrieved on 20200709], DOI: 10.1007/S11523-020-00735-9 [A] 1-15 * page 532 * DOI: http://dx.doi.org/10.1007/s11523-020-00735-9
		LINDSAY B. KILBURN: "The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial", vol. 30, no. 1, 17 November 2023 (2023-11-17), New York, pages 207 - 217, XP093169704, ISSN: 1078-8956, Retrieved from the Internet DOI: 10.1038/s41591-023-02668-y * the whole document * DOI: http://dx.doi.org/10.1038/s41591-023-02668-y
	International search	[XA] US2017173033 (BRAKE RACHAEL L et al.) [X] 1-9 * entire document especially para [0003]-[0004]; [0316] *[A] 10-12
		[A] US2020317659 (HIRANO SAYURI et al.) [A] 10-12 * entire document especially para [0002]; [000]-[0010]; [0013] *
		[A] US2019022243 (BOSHUIZEN JULIA et al.) [A] 1-12 * entire document *
		[A] US2018263979 (BOZON VIVIANA et al.) [A] 1-12 * entire document *
	Examination	LA MOTTE SANDY: "All parents should be outraged in fight against pediatric brain cancer, say two CNN correspondents", CNN, 7 September 2021 (2021-09-07), XP093352566, Retrieved from the Internet [retrieved on 20241229] [A] 1-15 * page 784 *
		TAKEBE TOHRU ET AL: "The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development", CTS - CLINICAL AND TRANSLATIONAL SCIENCE, vol. 11, no. 6, 1 November 2018 (2018-11-01), US, pages 597 - 606, XP093352571, ISSN: 1752-8054, DOI: 10.1111/cts.12577 [I] 1-15 * page 6 * DOI: http://dx.doi.org/10.1111/cts.12577

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.